Actinic Keratosis - Epidemiology Insights to 2023

  • ID: 4330788
  • Report
  • 40 pages
  • DelveInsight
1 of 3
Actinic Keratosis - Epidemiology Insights, 2023 provides an overview of the disease of the Actinic Keratosis for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Actinic Keratosis from 2013-2023.

Actinic Keratosis (AK) commonly known as a solar keratosis is a precancerous crusty lesion caused by damage from exposure to ultraviolet (UV) radiation. It is considered a pre-cancer condition if left untreated could develop into a skin cancer, most often squamous cell carcinoma (SCC). AKs appear on areas which are most commonly exposed to sun such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope:
  • The report provides historical as well as forecasted epidemiology of Actinic Keratosis in the 7MM.
  • The report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
Note: Please allow up to 48 hours for delivery of this report after payment has been made.
Note: Product cover images may vary from those shown
2 of 3
1. Report Introduction

2. Snapshot of Total Prevalent or Incident cases by 7 MM

3. Executive Summary
  • Key Findings
4. Actinic Keratosis Overview
  • Actinic Keratosis Definition
  • Pathophysiology
  • Symptoms
  • Etiology
5. Risk Factors Associated with Actinic Keratosis

6. Disease Burden & Unmet Need in the Market

7. Epidemiology and Patient Populations
  • Key Findings
  • Key Sources used and Forecast Methodology
  • Prevalent Cases and Incident Cases-2015-2025
  • Prevalent & Incident Cases by Category-2015-2025
  • Age-Specific Prevalent/ Incident Cases of Actinic Keratosis
  • Sex-Specific Prevalent/Incident Cases of Actinic Keratosis
  • Disease Type Specific Prevalent/Incident Cases of Actinic Keratosis
8.Prevalent & Incident Cases by 7 MM-2015-2025
  • Actinic Keratosis Epidemiology of United States-2025
  • Actinic Keratosis Epidemiology of United Kingdom-2025
  • Actinic Keratosis Epidemiology of Germany-2025
  • Actinic Keratosis Epidemiology of France-2025
  • Actinic Keratosis Epidemiology of Spain-2025
  • Actinic Keratosis Epidemiology of Italy-2025
  • Actinic Keratosis Epidemiology of Japan-2025
9. Key Takeaways

10. Appendix
11.Report Methodology

12. Consulting Services

13. Disclaimer

14. About Us

List of Tables
Table 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2013-2023)
Table 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2013-2023)
Table 3: Prevalent and Treatable Population of Actinic Keratosis in France (2013-2023)
Table 4: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2013-2023)
Table 5: Prevalent and Treatable Population of Actinic Keratosis in Italy (2013-2023)
Table 6: Prevalent and Treatable Population of Actinic Keratosis in Spain (2013-2023)
Table 7: Prevalent and Treatable Population of Actinic Keratosis in Japan(2013-2023)

List of Figures
Figure 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2013-2023)
Figure 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2013-2023)
Figure 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2013-2023)
Figure 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2013-2023)
Figure 5: Prevalent and Treatable Population of Actinic Keratosis in France (2013-2023)
Figure 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2013-2023)
Figure 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2013-2023)
Figure 8: IngenolDisoxate, Clinical Trials by Zone, 2017
Figure 9: Clinical Trials by Recruitment status, 2017
Figure 10: Number of Products under development by Companies, 2017
Figure 11: Clinical Stage Products, 2017
Figure 12: Pre-Clinical Stage Products, 2017
Figure 13: Assessment by Monotherapy Products, 2017
Figure 14: Assessment by Combination Products, 2017
Figure 15: Assessment by Route Of Administration, 2017
Figure 16: Assessment by Stage and Route Of Administration, 2017
Figure 17: Assessment by Molecule Type, 2017
Figure 18: Assessment by Stage and Molecule Type, 2017
Figure 19: Assessment by Stage of development and Domain, 2017
Figure 20: Assessment by Stage of development and Domain, 2017
Figure 21: Total Market size of Actinic Keratosis in USD Million (2013-2023)
Figure 22: United States Market Size of Actinic Keratosis in USD, Million (2013-2023)
Figure 23: Germany Market Size of Actinic Keratosis in USD, Million (2013-2023)
Figure 24: Italy Market Size of Actinic Keratosis in USD, Million (2013-2023)
Figure 25: Spain Market Size of Actinic Keratosis in USD, Million (2013-2023)
Figure 26: France Market Size of Actinic Keratosis in USD, Million (2013-2023)
Figure 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2013-2023)
Figure 28: Japan Market Size of Actinic Keratosis in USD, Million (2013-2023)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll